Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease
- Resource Type
- Abstract
- Source
- In
Blood 23 November 2021 138 Supplement 1:4162-4162 - Subject
- Language
- ISSN
- 0006-4971